Loader

Pathways

PathWhiz ID Pathway Meta Data

PW176637

Pw176637 View Pathway
drug action

Mianserin H1 Antihistamine Smooth Muscle Relaxation Action Pathway

Homo sapiens
Mianserin is an H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. Allergies causes blood vessel dilation which causes swelling (edema) and fluid leakage. Mianserin also inhibits the H1 histamine receptor on bronchiole smooth muscle myocytes. This normally activates the Gq signalling cascade which activates phospholipase C which catalyzes the production of Inositol 1,4,5-trisphosphate (IP3) and Diacylglycerol (DAG). Because of the inhibition, IP3 doesn't activate the release of calcium from the sarcoplasmic reticulum, and DAG doesn't activate the release of calcium into the cytosol of the endothelial cell. This causes a low concentration of calcium in the cytosol, and it, therefore, cannot bind to calmodulin.Calcium bound calmodulin is required for the activation of myosin light chain kinase. This prevents the phosphorylation of myosin light chain 3, causing an accumulation of myosin light chain 3. This causes muscle relaxation, opening up the bronchioles in the lungs, making breathing easier.

PW176730

Pw176730 View Pathway
drug action

Mianserin H1-Antihistamine Blood Vessel Constriction Action Pathway

Homo sapiens
Mianserin is an H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. Allergies causes blood vessel dilation which causes swelling (edema) and fluid leakage. Mianserin inhibits the H1 histamine receptor on blood vessel endothelial cells. This normally activates the Gq signalling cascade which activates phospholipase C which catalyzes the production of Inositol 1,4,5-trisphosphate (IP3) and Diacylglycerol (DAG). Because of the inhibition, IP3 doesn't activate the release of calcium from the sarcoplasmic reticulum, and DAG doesn't activate the release of calcium into the cytosol of the endothelial cell. This causes a low concentration of calcium in the cytosol, and it, therefore, cannot bind to calmodulin. Calcium bound calmodulin is required for the activation of the calmodulin-binding domain of nitric oxide synthase. The inhibition of nitric oxide synthesis prevents the activation of myosin light chain phosphatase. This causes an accumulation of myosin light chain-phosphate which causes the muscle to contract and the blood vessel to constrict, decreasing the swelling and fluid leakage from the blood vessels caused by allergens.

PW176822

Pw176822 View Pathway
drug action

Mianserin H1-Antihistamine Immune Response Action Pathway

Homo sapiens
Mianserin is an H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.

PW176548

Pw176548 View Pathway
metabolic

Mianserin Predicted Metabolism Pathway

Homo sapiens
Metabolites of Mianserin are predicted with biotransformer.

PW127636

Pw127636 View Pathway
drug action

Micafungin Action Pathway

Homo sapiens
Micafungin, also known as Mycamine, is an echinocandin antifungal agent used for the treatment of candidemia, acute disseminated candidiasis, and certain other fungal infections..More commonly, Micafungin is used against Aspergillus infections, and only used against some Candida infections. It is also used to treat the prophylaxis of Candida infections during stem cell transplantation. It is a glucan synthesis inhibitor which is essential for cell wall synthesis. Micafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This prevents the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall, which ultimately leads to osmotic instability and cell death.

PW145229

Pw145229 View Pathway
drug action

Micafungin Drug Metabolism Action Pathway

Homo sapiens

PW127390

Pw127390 View Pathway
drug action

Miconazole Action Pathway

Homo sapiens
Miconazole is an azole antifungal used to treat fungal infections affecting the vagina, mouth and skin, including candidiasis. Miconazole has some activity against Gram-positive bacteria as well. It is known by the brand names Aloe Vesta Antifungal, Baza, Critic-aid Clear, Desenex, Fungoid, Inzo, Lagicam, Lotrimin AF, Micatin, Micro-guard, Monistat, Monistat 1 Day Ovule Combination Pack, Monistat 3 Day Ovule Combination Pack, Monistat 7 Combination Pack, Oravig, Rash Relief Antifungal, Remedy Antifungal, Tetterine, Tineacide Antifungal, Ting, Vagistat, Vagistat 3 Day Combination Pack, Vusion, or Zeasorb. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available. The primary mechanism of action is through inhibition of the CYP450 14α-lanosterol demethylase enzyme.Lanosterol 14-alpha demethylase is the enzyme that catalyzes the synthesis of 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol from lanosterol. With this enzyme inhibited ergosterol synthesis cannot occur which causes a significant low concentration of ergosterol in the fungal cell. Ergosterol is essential in maintaining membrane integrity in fungi. Without ergosterol, the fungus cell cannot synthesize membranes thereby increasing fluidity and preventing growth of new cells, which in turn leads to cation, phosphate, and low molecular weight protein leakage.. This leads to cell lysis which causes it to collapse and die. Additionally, miconazole inhibits fungal peroxidase and catalase while not affecting NADH oxidase activity, leading to an accumulation of hydrogen peroxide, which further leads to cell toxicity and death. It also leads to an increased production of reactive oxygen species (ROS). Increased intracellular ROS leads to downstream pleiotropic effects and eventual apoptosis. Lastly, likely as a result of lanosterol demethylation inhibition, miconazole causes a rise in intracellular levels of farnesol. This molecule participates in quorum sensing in Candida, preventing the transition from yeast to mycelial forms and thereby the formation of biofilms, which are more resistant to antibiotics.

PW145199

Pw145199 View Pathway
drug action

Miconazole Drug Metabolism Action Pathway

Homo sapiens

PW176457

Pw176457 View Pathway
metabolic

Miconazole Predicted Metabolism Pathway

Homo sapiens
Metabolites of Miconazole are predicted with biotransformer.

PW146768

Pw146768 View Pathway
drug action

Microcrystalline cellulose Drug Metabolism Action Pathway

Homo sapiens